Advertisement

Infection

, Volume 23, Issue 3, pp 143–148 | Cite as

Pattern of soluble TNF receptors I and II in sepsis

  • J. Schröder
  • B. Kremer
  • F. Stüber
  • H. Gallati
  • F. U. Schade
Originalia

Summary

The serum levels of soluble TNF receptors I (sTNFR I) and sTNFR II were measured frequently in 14 patients with sepsis to evaluate the pattern of these TNF antagonists in relation to TNF alpha, Soluble TNFR I and II could be detected in all samples with significantly higher levels (p<0.001) compared to healthy controls. The concentration of sTNFR I as well as sTNFR II was significantly higher in nonsurvivors compared to survivors during the first 36 h of sepsis (p<0.001). Levels remained elevated throughout the evaluation with maximal values in patients who died. A positive correlation exists between both receptors and between soluble receptors and simultaneously obtained sepsis score (p<0.01) while TNF immunoreactivity detected in 80% of all samples did not correlate to soluble receptor levels or sepsis score. Soluble receptors were constantly found in the circulation representing the inflammatory state throughout the evaluation even when TNF activity was undetectable.

Keywords

Public Health Internal Medicine Infectious Disease Serum Level General Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Kinetik der löslichen TNF-Rezeptoren I und II bei Sepsis

Zusammenfassung

Die Serumspiegel der löslichen TNF-Rezeptoren I (sTNFR I) und II (sTNFR II) wurden in kurzen Zeitabständen bei 14 Patienten mit der Diagnose einer Sepsis bestimmt, um die Kinetik der natürlich vorkommenden TNF-Antagonisten in Relation zu TNF alpha zu untersuchen. Die sTNFR I und II waren signifikant gegenüber gesunden Kontrollprobanden erhöht (p<0,001). Die Serumkonzentrationen sowohl des sTNFR I als auch des sTNFR II waren während der ersten 36 Stunden der Sepsis bei den Patienten, die verstarben, signifikant höher als bei den Überlebenden (p<0,001). Die Konzentrationen blieben während der weiteren Messungen erhöht und zeigten maximale Werte bei Patienten mit einem letalen Ausgang. Eine positive Korrelation bestand zwischen den beiden löslichen Rezeptoren sowie den Rezeptoren und dem gleichzeitig bestimmten Sepsis Score (p<0,01), während die Immunreaktivität von TNF alpha, die in 80% aller Proben gemessen wurde, keine positive Korrelation zu den löslichen TNF-Rezeptoren oder dem Sepsis Score aufwies. Die löslichen TNF-Rezeptoren I und II können während der Sepsis zu jedem Zeitpunkt und auch dann nachgewiesen werden, wenn keine meßbare TNF-Aktivität vorliegt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vassali, P. The pathophysiology of tumor necrosis factor. Ann. Rev. Immunol. 10 (1992) 411–452.Google Scholar
  2. 2.
    Deitch, E. A. Multiple organ failure. Ann. Surg. 216 (1992) 117–134.Google Scholar
  3. 3.
    Waage, A., Halstensen, A., Espevik, T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet i (1987) 355–357.Google Scholar
  4. 4.
    Lowry, S. E. Cytokine mediators of immunity and inflammation. Arch. Surg. 128 (1993) 1235–1241.Google Scholar
  5. 5.
    Gehr, G., Gentz, R., Brockhaus, M., Loetscher, H., Lesslauer, W. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J. Immunol. 149 (1992) 911–917.Google Scholar
  6. 6.
    Ware, C. F., Crowe, P. D., Vanarsdale, T. L., Andrews, J. L., Grayson, M. H., Jerzy, R., Smith, C. A., Goodwin, R. G. Tumor necrosis factor (TNF) receptor expression in T-lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J. Immunol. 147 (1991) 4229–4238.Google Scholar
  7. 7.
    Tartaglia, L. A., Weber, R. F., Figsri, I. S., Reynolds, C., Palladino, M. A., Goedell, D. V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. (USA) 88 (1991) 9292–9296.Google Scholar
  8. 8.
    Tsujimoto, M., Vilcek, J. Tumor necrosis factor receptors in HeLa cells and their regulation by interferon gamma. J. Biol. Chem. 261 (1986) 5384–5388.Google Scholar
  9. 9.
    Kohno, T., Brewer, M. T., Baker, S. L., Schwartz, P. E., King, M. W., Hale, K. K., Squires, C. H., Thompson, R. C., Vannice, J. L. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. (USA) 87 (1990) 8331–8335.Google Scholar
  10. 10.
    Loetscher, H., Pan, Y.-C. E., Lahm, H. W., Gentz, R., Brockhaus, M., Tabuchi, H., Lesslauer, W. Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell 61 (1990) 351–359.Google Scholar
  11. 11.
    Smith, C. A., Davies, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D., Goodwin, R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248 (1990) 1019–1023.Google Scholar
  12. 12.
    Froon, A. H., Bemelmanns, M. H., Greve, J. W., van der Linden, C. J., Buurman, W. A. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit. Care Med. 22 (1994) 803–809.Google Scholar
  13. 13.
    Rogy, M. A., Coyle, S. M., Oldenburg, H. S. A., Rock, C. S., Barie, P. S., Van Zee, K. J., Smith, C. G., Moldawer, L. L., Lowry, S. F. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J. Am. Coll. Surg. 178 (1994) 132–138.Google Scholar
  14. 14.
    Girardin, E., Roux-Lombard, P., Grau, G. E., Suter, P., Gallati, H., Dayer, J.-M. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 76 (1992) 20–23.Google Scholar
  15. 15.
    Van Zee, K. J., Kohno, T., Fischer, E., Rock, C. S., Moldawer, L. L., Lowry, S. F. TNF soluble receptors protect against excessive TNF alpha during infection and injury. Proc. Natl. Acad. Sci. (USA) 89 (1992) 4845–4849.Google Scholar
  16. 16.
    Adolf, G. R., Fruhbeis, B. Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. Cytokine 4 (1992) 180–184.Google Scholar
  17. 17.
    Bone, R. C., Sprung, C. L., Sibbald, W. J. Definitions for sepsis and organ failure. Crit. Care Med. 20 (1992) 724–726.Google Scholar
  18. 18.
    Elebute, E. A., Stoner, H. B. The grading of sepsis. Br. J. Surg. 70 (1983) 29–31.Google Scholar
  19. 19.
    Zabel, P., Schönharting, M. M., Wolter, D. T., Schade, U. F. Oxpentifylline in endotoxaemia. Lancet 334 (1989) 1474–1477.Google Scholar
  20. 20.
    Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., Wilmore, D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318 (1988) 1481–1486.Google Scholar
  21. 21.
    Tracy, K. J., Lowry, S. F., Fahey, T. J. 3rd, Albert, J. D., Fong, Y., Hesse, D., Beutler, B., Manogue, K. R., Calvano, S., Wei, H., Cerami, A., Shires, G. T. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164 (1987) 415–422.Google Scholar
  22. 22.
    Tracy, K. J., Fong, Y., Hesse, D., Manogue, K. R., Lee, A. T., Kuo, G., Lowry, S. F., Cerami, A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330 (1987) 662–664.Google Scholar
  23. 23.
    Ertel, W., Morrison, M. H., Wang, P., Zheng, F., Ayala, A., Chaudry, I. H. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin and interleukins. Ann. Surg. 214 (1991) 141–148.Google Scholar
  24. 24.
    Tracy, K. J. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ. Shock 35 (1991) 123–128.Google Scholar
  25. 25.
    Fong, Y., Moldawer, L. L., Shires, G. T., Lowry, F. The biological characteristics of cytokines and their implications in surgical injury. Surg. Gynecol. Obstet. 170 (1990) 363–378.Google Scholar
  26. 26.
    Engelberts, I., Stephens, S., Francot, G. J. M., Van der Linden, C. J., Buurman, W. A. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338 (1991) 515–516.Google Scholar
  27. 27.
    Nophar, Y., Kemper, O., Brakebusch, C., Engelmann, H., Zwang, R., Aderka, D., Holtmann, H., Wallach, D. Soluble forms of tumor necrosis factor receptors (TNF-R's). The cDNA for the type I TNFR cloned using amino acid data of its soluble form, encodes for both the cell surface and a soluble form of the receptor. EMBO J. 9 (1990) 3269–3278.Google Scholar
  28. 28.
    Thompson, W. A., Coyle, S., Van Zee, K., Oldenburg, H., Trousdale, R., Rogy, M., Felsen, D., Moldawer, L., Lowry, S. F. The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch. Surg. 129 (1994) 72–79.Google Scholar
  29. 29.
    Lesslauer, W., Tabuchi, H., Gentz, R., Brockhaus, M., Schlaeger, E. J., Grau, G., Piguet, P. F., Pointaire, P., Vassalli, P., Loetscher, H. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21 (1991) 2883–2886.Google Scholar
  30. 30.
    Ashkenazi, A., Marsters, S. A., Capon, D. J., Chamow, S. M., Figari, I. S., Pennica, D., Goeddel, D. V., Palladino, M. A., Smith, D. H. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl. Acad. Sci. (USA) 88 (1991) 10535–10539.Google Scholar
  31. 31.
    Wong, G. H., Tartaglia, L. A., Lee, M. S., Goeddel, D. V. Antiviral activity of tumor necrosis factor is signaled through the 55 kDa receptor, type I TNF. J. Immunol. 149 (1992) 3350–3353.Google Scholar
  32. 32.
    Pfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M., Mak, T. W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb toL. monocytogenes infection. Cell 73 (1993) 457–467.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH 1995

Authors and Affiliations

  • J. Schröder
    • 1
  • B. Kremer
    • 1
  • F. Stüber
    • 2
  • H. Gallati
    • 3
  • F. U. Schade
    • 4
  1. 1.Klinik für Allgemeine Chirurgie und ThoraxchirurgieKlinikum der Christian-Albrechts-Universität zu KielKielGermany
  2. 2.Klinik für Anästhesiologie und operative IntensivmedizinKlinikum der Christian-Albrechts-Universität zu KielKielGermany
  3. 3.Hoffmann-La RocheBaselSchweiz
  4. 4.Forschungsinstitut BorstelBorstelGermany

Personalised recommendations